Form 8-K - Current report:
SEC Accession No. 0001213900-25-003421
Filing Date
2025-01-14
Accepted
2025-01-14 16:16:08
Documents
15
Period of Report
2025-01-08
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea022765801-8k_enzobiochem.htm   iXBRL 8-K 25513
2 PRESS RELEASE OF ENZO BIOCHEM, INC. DATED JANUARY 14, 2025 ea022765801ex99-1_enzobio.htm EX-99.1 6760
3 GRAPHIC image_004.jpg GRAPHIC 3750
  Complete submission text file 0001213900-25-003421.txt   213544

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE enz-20250108.xsd EX-101.SCH 3030
5 XBRL LABEL FILE enz-20250108_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE enz-20250108_pre.xml EX-101.PRE 22370
17 EXTRACTED XBRL INSTANCE DOCUMENT ea022765801-8k_enzobiochem_htm.xml XML 3557
Mailing Address ENZO BIOCHEM INC 60 EXECUTIVE BLVD FARMINGDALE NY 11735
Business Address 60 EXECUTIVE BLVD FARMINGDALE NY 11735 5167555500
ENZO BIOCHEM INC (Filer) CIK: 0000316253 (see all company filings)

EIN.: 132866202 | State of Incorp.: NY | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-09974 | Film No.: 25529553
SIC: 8071 Services-Medical Laboratories
(CF Office: 08 Industrial Applications and Services)